ArticleBritish journal of cancer2015

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.

Elodie Jobard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.